 | |
| Clinical data | |
|---|---|
| Trade names | Xegafri |
| Other names | CO-1686, AVL-301 |
| Routes of administration | By mouth |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C27H28F3N7O3 |
| Molar mass | 555.562 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Rociletinib is a medication developed to treatnon-small cell lung carcinomas with a specific mutation. It is a third-generationepidermal growth factor receptortyrosine kinase inhibitor.[1] It was beingdeveloped byClovis Oncology as a potential treatment fornon-small-cell lung cancer.[1] In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew itsmarketing authorisation application from theEuropean Medicines Agency.[1]
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |
